Factors associated with achieving minimally symptomatic status by patients with schizophrenia: results from the 3-year intercontinental schizophrenia outpatients health outcomes study
- 1 May 2010
- journal article
- clinical trial
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 64 (6) , 697-706
Abstract
The aim of this study was to describe factors associated with achieving a minimally symptomatic status outcome in outpatients with schizophrenia. Data were analysed from a 3-year, prospective observational study that examined outcomes in 7658 patients with schizophrenia. Minimally symptomatic status was defined as a postbaseline score of 1 or 2 on the Clinical Global Impressions Severity Scale-Schizophrenia version (CGI-SCH). Baseline CGI-SCH score had the strongest association with minimally symptomatic status followed by age, geographical region and hospitalisation status. The probability of becoming minimally symptomatic was consistently higher in the olanzapine and risperidone monotherapy groups compared with the clozapine, quetiapine or haloperidol groups [corrected]. The olanzapine group achieved the minimally symptomatic status in a shorter period of time than the other treatment groups (p < or = 0.016). The likelihood of patients achieving a minimally symptomatic status was greater in younger patients with lower baseline clinical severity and in patients whose treatment included olanzapine.Keywords
This publication has 26 references indexed in Scilit:
- Definitions of response and remission in schizophrenia: recommendations for their use and their presentationActa Psychiatrica Scandinavica, 2008
- Long-Term Antipsychotic Monotherapy for SchizophreniaThe Journal of Clinical Psychiatry, 2008
- Standardized Remission Criteria in Schizophrenia: Descriptive Validity and Comparability with Previously Used Outcome MeasuresPharmacopsychiatry, 2008
- The Portuguese version of the Clinical Global Impression - Schizophrenia Scale: validation studyBrazilian Journal of Psychiatry, 2007
- Response and Relapse in Patients With Schizophrenia Treated With Olanzapine, Risperidone, Quetiapine, or HaloperidolThe Journal of Clinical Psychiatry, 2005
- Remission in Schizophrenia: Proposed Criteria and Rationale for ConsensusAmerican Journal of Psychiatry, 2005
- Sustained Remission of Schizophrenia Among Community-Dwelling Older OutpatientsAmerican Journal of Psychiatry, 2004
- Effectiveness of Antipsychotic Treatments for SchizophreniaThe Journal of Clinical Psychiatry, 2004
- A Double-Blind, Randomized, Placebo-Controlled Trial of Olanzapine in the Prevention of Psychotic RelapseJournal of Clinical Psychopharmacology, 2003
- Long-Term Course of Schizophrenic Illness: Bleuler’s Study ReconsideredAmerican Journal of Psychiatry, 2003